Medicine and Health

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

K. Shitara, Y. Bang, et al.

Trastuzumab deruxtecan (T-DXd) has shown promising clinical advancements for patients with HER2+ gastric cancer, according to the DESTINY-Gastric01 trial. Engaging explorations into HER2 biomarkers and resistance mechanisms highlight correlations that could shape future therapies. This vital research was led by an exceptional team of authors.

00:00

Playback language: English

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

J. Cortés, S. A. Hurvitz, et al.

Medicine and Health

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

N. Harbeck, E. Ciruelos, et al.

Medicine and Health

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

B. Besse, E. Pons-tostivint, et al.

Medicine and Health

Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial

S. Peters, S. M. Gadgeel, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny